Search Results

Joseph Kim exploring GPCR structural biology, cryo-electron microscopy, opioid receptor pharmacology, Joseph Kim is a structural biologist studying membrane proteins and GPCR pharmacology. molecular structures inform the design and development of new therapeutics. GPCR Drug Discovery Is Increasingly Structural Modern GPCR drug discovery increasingly integrates structural You could easily imagine separate therapeutic programs targeting those different physiological effects

optimize the design and engineering of more efficacious therapeutics. perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Biologist - Confo Therapeutics Associate Director/Director, Platform & Hit-ID Chemistry Lead - Septerna Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic

The therapeutic mechanism, however, is inseparable from the psychedelic experience itself, and not every questions in current GPCR pharmacology: can biased signaling at the serotonin 2A receptor decouple the therapeutic What you usually can't do is know which pathway, in which disease, will actually be therapeutic. The premise: psilocybin's therapeutic effect on depression is now well documented, but it is locked to Six weeks in, structures are turning over and chemistry is iterating.

Fiona Marshall on structure-based GPCR drug discovery, the GABA-B heterodimer, the acetate that rewrote routine, the insight that seeded Heptares Therapeutics. She co-founded Heptares Therapeutics and served as Chief Scientific Officer for twelve years, through Structures Reveal Pockets the Field Didn't Know Existed Once GPCR structures became routine, unexpected As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

His main research group centers on the function, structure, and regulation of G protein-coupled receptors Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics

This session addresses the structural and strategic decisions that determine whether breakthrough science As co-founder and CEO of Keltic Pharma Therapeutics, he leads a biotechnology company developing a novel His recent work on muscarinic acetylcholine receptor modulation and structure-guided design of M1 receptor

Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Kobilka’s lab contributing to the elucidation of high-resolution structures of various GPCRs. Dr. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr.

daLUXendin Family Fluorescent dual agonists for both GLP-1R and GIPR (daLUXendin544+ and daLUXendin660+), structurally His work carries direct translational relevance to diabetes and obesity therapeutics. It provides curated industry intelligence, expert-led masterclasses, and structured engagement opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic drug discovery trends and developments Expert-led webinars and masterclasses with leading researchers Structured

Her work involves the pharmacological and structural characterisation of novel putative antipsychotic molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

field of pharmacology and biochemistry of GPCR and the crucial role of the lipidic environment on their structure In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

. 🗓️ Upcoming 4-Week Course: Development of GPCR Ligands as Therapeutic Drugs starting March 20 – April biotechs public Aikium's AI-Driven mRNA Engine Looks to Address Undruggable Disordered Proteins Tectonic Therapeutic - 21, 2025 | 2nd GPCR signaling and drug discovery Symposium & Workshop NEW April 2 - 3, 2025 | New therapeutic Pharmacology 2025 July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Structural PhD Position GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

Designed for structural pharmacologists, cell biologists, and drug discovery scientists working on GPCR systems where spatial organization influences therapeutic outcomes.

Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights concentrations, her work highlights why receptor localization and protein complex assembly matter for therapeutic How an integrated training and lab structure at Monash Institute of Pharmaceutical Sciences fosters innovation localized signaling events, how these mechanisms are hijacked in disease, and how they can be leveraged for therapeutic

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics discovery, he later co-founded Superluminal Medicines, a company using machine learning to explore GPCR structure-function

Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics expertise and provides you with product solutions including cell-based assays for basic research through therapeutic Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic Explore GLP-1 Product Solutions to Support Obesity/Diabetes See GLP-1 Solutions Accelerating Obesity Therapeutics These GPCRs are excellent for use in functional, structural, or identification assays.

Anita Nivedha discusses computational approaches to decoding signal propagation within GPCR structures observed signaling outcomes, providing a bridge between structural biology and pharmacology. visualization to become quantitative tools for understanding receptor activation and guiding GPCR-targeted therapeutics ligand bias inside receptor structures? That transmission happens through communication pathways across the receptor structure.

Nicola J Smith is an expert in molecular pharmacology with a track record in exploring GPCR structure-function orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic

Each session explores mechanistic models, translational challenges, and real-world therapeutic implications These webinars are ideal for: • GPCR pharmacologists • Medicinal chemists working on receptor targets • Structural Calcium and signaling assays • Drug–receptor kinetics • Translational pharmacology strategies • GPCR structure–function

Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic Operational Discipline I instill structure and consistency across every phase of your discovery process Yamina brings the clarity, rigor, and structured decision-making that keeps programs on track. Abishek Iyer, CEO Ashta Therapeutics Before working with Yamina, we had solid internal momentum but needed Her input helped us structure the screening funnel, define clear go/no-go criteria, and integrate ADME

During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic

allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic

allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics the relocation of some university labs to facilitate collaboration and overcome the siloed department structure Additionally, they explored the unique culture and structure of their Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic commercialization.

allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics the relocation of some university labs to facilitate collaboration and overcome the siloed department structure Additionally, they explored the unique culture and structure of their Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic commercialization.

. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes 📌 Measuring Bias: A Quantitative Approach 🔹 The operational model provides a structured way to measure

working with distinct chemical scaffolds like thiazolidines and xanthinediones, Ben is helping define how structurally team aims to understand how and where these compounds interact with the receptor, paving the way for structure-based Structural Biology Roadblocks: The Cryo-EM Challenge One bottleneck in Ben’s work is visualizing binding Still, by collaborating with structural biology teams and combining cryo-EM with NMR , his lab is narrowing Clements' work is primarily focused on translational developments of small molecule therapeutics, and

neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic collaborative chemistry enabled in designing receptor-targeted fluorescent ligands The moment when structural

Jacobson, Matteo Pavan Structure-Based Design of Modulators of Purinergic GPCRs <p class="font_8">Watch Unconventional GPCR Ligands <p class="font_8">Watch Now</p> Terry Kenakin The New Frontier of GPCR Therapeutics Matteo Pavan NIH Computational Chemist Driving Structure-Based Drug Discovery | Molecular Modeling | Structure-Based Drug Design Innovation & Strategic Application Agonists, Antagonists & Core Mechanisms

Clinical insights on tachyphylaxis, tolerance, and kinetic-based therapeutics. < Back How Signaling Kinetics kinetics, the temporal dynamics of receptor activation and downstream signaling, directly influence therapeutic spans tachyphylaxis mechanisms in beta-agonist therapy, tolerance development with opioid agonists, and therapeutic pharmacologists, drug discovery scientists, and translational researchers working on temporal aspects of GPCR therapeutics specializing in kinetic analysis of drug action and the application of binding and signaling kinetics to therapeutic

of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics able to work with him and his team and use the tools developed in his lab to better understand GPCR structure